| Oct 2 |
Shattuck Labs Refocuses Strategy Amidst Restructuring and Cuts
|
| Oct 1 |
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
|
| Oct 1 |
Shattuck plunges after discontinuing lead candidate
|
| Oct 1 |
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
|
| Sep 25 |
Shattuck Labs, Inc. (NASDAQ:STTK) is definitely on the radar of institutional investors who own 43% of the company
|
| Aug 2 |
Shattuck Labs GAAP EPS of -$0.42, revenue of $1.61M
|
| Aug 1 |
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 1 |
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Jul 30 |
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
|
| Jul 12 |
Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
|
